HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Single-agent thalidomide induces response in T-cell lymphoma.

Abstract
T-cell lymphoma is an aggressive lymphoma that cannot be cured despite aggressive therapy, including autologous stem cell transplantation. Thalidomide is an immunomodulatory drug with numerous properties that has proven effective in relapsed multiple myeloma and, to a lesser extent, in other hematologic diseases. We report three cases of relapsed refractory T-cell lymphoma treated with thalidomide with a good tumor response.
AuthorsG Damaj, R Bouabdallah, N Vey, K Bilger, M Mohty, J A Gastaut
JournalEuropean journal of haematology (Eur J Haematol) Vol. 74 Issue 2 Pg. 169-71 (Feb 2005) ISSN: 0902-4441 [Print] England
PMID15654910 (Publication Type: Case Reports, Journal Article)
Copyright(c) Blackwell Munksgaard 2005
Chemical References
  • Immunosuppressive Agents
  • Thalidomide
Topics
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Immunosuppressive Agents (administration & dosage)
  • Lymphoma, T-Cell (drug therapy, pathology)
  • Male
  • Middle Aged
  • Multiple Myeloma (drug therapy)
  • Neoplasm Recurrence, Local (drug therapy)
  • Thalidomide (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: